J&J Will Take $600 Million Charge to Pay for Lawsuits

Johnson & Johnson (JNJ) will set aside $600 million in the second quarter to increase its reserves for potential settlements of civil lawsuits alleging it illegally marketed drugs including the anti-psychotic Risperdal.

J&J established a $1.7 billion fund in 2011 for litigation settlements, the New Brunswick, New Jersey-based company said in its January earnings report. An Arkansas state judge in April ordered J&J to pay more than $1.1 billion for illegally marketing and misleading doctors and patients about the risks of Risperdal starting in 2002. J&J, the world’s top seller of health-care products, said it will appeal.

The $600 million will be used if settlements are reached in previously disclosed civil cases regarding Risperdal, the anti- psychotic Invega and Omnicare Inc. (OCR), which distributes pharmaceuticals to nursing homes and assisted living facilities, J&J said yesterday in a statement. The money will also be used for cases involving the heart failure drug Natrecor. J&J pleaded guilty to misbranding the drug in September and agreed to pay an $85 million fine.

Bill Price, a J&J spokesman, said the company wouldn’t comment beyond the statement.

J&J gained less than 1 percent to $62.98 yesterday at the close in New York. The shares have declined 4.8 percent in the past 12 months.

The U.S. Justice Department demanded in March that J&J pay about $1.8 billion to resolve the civil claims by the U.S. and some states, an increase from a $1 billion settlement that had been negotiated by the U.S. Attorney’s Office in Philadelphia in late December.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.